October 8, 2020
From the event website:
Join MDMA research pioneers Michael Mithoefer, MD and Annie Mithoefer, BSN for an in-depth exploration of the history, present, and future of MDMA-assisted psychotherapy for clinical applications such as treatment of PTSD and depression.
The MDMA Therapy Training Program, run by MAPS Public Benefit Corporation, prepares clinicians to provide MDMA-Assisted Therapy in approved protocols.
As clinical trials progress in the United States, Canada, Israel, and the European Union, the potential for MDMA-assisted psychotherapy for PTSD to become an approved prescription treatment looks more and more promising.
Clinicians interested in new treatment options for PTSD can learn about the treatment design and published study outcomes as they consider how MDMA-assisted psychotherapy might serve their patient populations.
This workshop will explore important considerations for clinicians interested in becoming an MDMA-Assisted Therapy Practitioner, including:
-
Qualifications and skillset
-
Training requirements
-
Building competency to work with non-ordinary states of consciousness
-
The co-therapy model
-
Ethical practice, and
-
Patient access to treatment.
Core elements of the therapeutic approach will be discussed as they relate to theoretical understanding and practice of the modality, including: inner healing intelligence, inner-directed process, trusting the process, beginner’s mind, somatic manifestations, safety, support, therapeutic alliance, and trust.
The presenters bring case examples and first-hand experience from their work on the MAPS-sponsored MDMA-assisted psychotherapy clinical trials to share in a lively day of presentation, discussion, and experiential activity.
We offer Continuing Education (CE) and Continuing Medical Education (CME) credits for most doctors, therapists, psychologists, nurses, and social workers in the United States.
For more information, visit the event website.
